We present a case of acute pulmonary oedema as the first presentation of autoimmune cardiomyopathy in primary antiphospholipid antibody syndrome in a patient who had no previous cardiac history. Five days of methylprednisolone at 500 mg/day followed by 100 mg/day for 10 days and then a weaning course of oral prednisone resulted in effective resolution of the acute diffuse cardiomyopathy. Her cardiac status became clinically and echocardiographically normal. We illustrate the effectiveness of immunosuppressive therapy as an adjunct to standard anti-failure measures in such presentations and we outline the association between antiphospholipid antibodies and cardiac dysfunction.
The term "antiphospholipid antibody syndrome" (APS) describes patients who have persistent elevation of antiphospholipid antibodies (APAs) of which anticardiolipin has been the most frequently investigated 1 . APS is deemed to be present when a patient has raised APAs and one of the following clinical conditions: venous or arterial thrombosis, neurologic disease, thrombocytopenia or recurrent fetal wastage 2 .
APA designates a heterogeneous group of immunoglobulins (IgG, IgM, and, rarely, IgA) detectable by two kinds of tests: (a) solid phase immunoassays, typically ELISA, which detects antibodies to cardiolipin-bound beta-2 glycoprotein I as well as to cardiolipin (phospholipid specific antibodies) and (b) phospholipid-dependent coagulation tests, by virtue of the ability of some APAs to impair in vitro coagulation reactions 3 . APAs detected by the conventional ELISA test with anionic phospholipid cardiolipin are termed anticardiolipins (ACL) 4 , whereas those identified in the coagulation tests are labeled lupus anticoagulant (LAC) 5 .
Antiphospholipid antibody syndrome may be primary (PAPS) when it occurs in the absence of lupus and allied disorders as in half the patients with APS, or secondary to SLE as in the other 50% of APS population 6 . Cardiac abnormalities are not uncommon in patients with systemic lupus erythematosus (SLE). However, data on cardiac abnormalities in primary APS is scarce, due to low incidence or under-recognition. We present a case of acute autoimmune cardiomyopathy in primary antiphospholipid antibody syndrome.
CASE REPORT
A previously healthy 47-year-old woman suffered a de novo left lower limb deep venous thrombosis. There were no stigmata of SLE or connective tissue disease. Tests for inherited thrombophilia revealed a positive lupus anticoagulant with a kaolin clotting time of 230 seconds (normal 20-72 s) and a dilute Russell viper venom test >150 s (normal <45 s). Her sample normalized to the addition of excess phospholipid thus confirming LAC. IgG anticardiolipin was elevated at >64 U/ml (normal <10) with an IgM-ACL of 3 U/ml (normal <10). She was treated with unfractionated heparin followed by warfarin.
Two months later she underwent an abdominal hysterectomy to remove a myoma. Ten days after her hysterectomy, she suffered acute pulmonary oedema. A chest radiograph showed new cardiomegaly and florid pulmonary oedema and an ECG revealed non-progression of "R" waves from V1-V3 with no ST segment abnormality. She was managed with continuous positive pressure mechanical ventilation, frusemide and dobutamine. Soon after intubation her central venous pressure was 11 mmHg and, on dobutamine 5 µg/kg/min, her mean arterial pressure (MAP) was 70 mmHg. She became oliguric.
A transthoracic echocardiogram showed marked left ventricular systolic dysfunction and a large pericardial effusion. Mild right ventricular free wall inversion was noted. Valvular structures were normal. Her P a O 2 was 90 mmHg on 100% oxygen. Swan-Ganz catheterization revealed a pulmonary capillary wedge pressure (PCWP) of 40 mmHg, pulmonary artery (PA) pressures of 55/30 mmHg and a cardiac index of 2.58 l/min/m 2 . SVR was 1,000 dyn/s/cm 5 . By this time her therapy included adrenaline 9 µg/min and dobutamine 10 µg/kg/min. Nitric oxide 40 ppm was added after PA pressures rose to 70/40 mmHg.
A transoesophageal echocardiogram (TOE), in addition to confirming the transthoracic echogram findings, revealed moderate to severe mitral regurgitation with flow reversal in the pulmonary veins which was due to a failure of coaptation of the mitral leaflets. There was no prolapse, flail segment or vegetation. The right ventricle was hypokinetic and the pulmonary arteries were enlarged.
Pericardiocentesis drained 300 ml of strawcoloured sterile fluid with 54 g/l of protein and 1,720 U/l of lactic dehydrogenase (LDH). Reactive mesothelial cells, histiocytes and occasional lymphocytes were seen but there were no malignant cells. Angiocardiography revealed normal coronary arteries, global biventricular dysfunction and mitral regurgitation with left ventricular end diastolic pressure (LVEDP) at 39 mmHg. Cardiac index at this point was 3.22 l/min/m 2 , SVR 500 dyn/s/cm 5 and MAP 55 mmHg. Subsequent adrenaline at 26 µg/min and noradrenaline 14 µg/min increased the MAP.
Autoimmune cardiomyopathy was suspected and methylprednisolone 500 mg IV daily was commenced. Autoimmune test profile is shown in Table 1 .
During the first two days a good diuresis was obtained and her lungs improved to a P a O 2 /FiO 2 ratio of 268 on FiO 2 of 0.4. Her dynamics at this stage revealed PA=40/24; PCWP=19; cardiac index (CI)=2.58 l/min/m 2 and systemic vascular resistance (SVR)=963 dyn/s/cm 5 on adrenaline 3 µg/min and noradrenaline 4 µg/min. Nitric oxide was weaned slowly.
A repeat TOE on day 3 showed moderate biventricular dysfunction and severe mitral regurgitation but no pericardial effusion. Echo features were consistent with a cardiomyopathic process.
During the next four to five days her cardiogenic shock improved steadily but her course was complicated by (a) pseudomonas pneumonia, (b) septic shock and (c) acute renal failure. Bronchoalveolar lavage revealed a cell count of 21% macrophages, 16% lymphocytes and 63% neutrophil polymorphs. Antibiotic therapy and continuous venovenous haemodiafiltration (CVVHDF) resulted in gradual improvement of her condition. On day 7, she developed a right lower limb proximal deep vein thrombosis; this was managed by high-intensity anticoagulation and inferior vena cava filter. She was extubated nine days after her initial presentation.
From day 10, a smaller dose of methylprednisolone 100 mg/day was instituted, as was a titrated dose of captopril. She was then transferred to the medical ward with sinus tachycardia at 96/min, MAP 74 mmHg and normal renal function. Steroid therapy was changed to oral prednisone 1 mg/kg/day. Her cardiac function improved gradually and sequential TOE confirmed the gradual return of LV function. Mycophenolate was introduced enabling a wean from steroids. Forty days after her acute presentation she was clinically much improved with no overt signs of cardiac dysfunction. Her therapy at this juncture consisted of mycophenolate 1g twice daily, prednisone 10 mg daily, perindopril 4 mg daily, frusemide 10 mg daily and warfarin.
Two years later she is completely well on an angiotensin converting enzyme inhibitor, mycophenolate and warfarin; serial echocardiography confirmed cardiac normality. 
DISCUSSION
The antiphospholipid antibodies, which include the LAC and ACL, are a group of antibodies directed predominantly against anionic phospholipids 2, 4, 5 . When these antibodies are seen with thrombotic or neurological disorders, thrombocytopenia or fetal loss, the syndrome of APS is present 2 . Increased levels of APAs are common in infections 7 and malignancies but in these situations clinical APS is not seen 3 .
There is only a partial overlap between the antigenic specificities of antibodies measured by ACL and LAC assays 3 . An individual patient may have only ACL, only LAC, or both types of APAs simultaneously that may either appear to be a single antibody population or distinct and physically separable. The association between LAC and thrombotic episodes is well established but evidence for a link between ACL and thrombosis (in the absence of LAC) is weaker 2 .
Cardiac abnormalities in secondary APS are well documented 3, 8 . SLE patients with APAs have a higher prevalence of nonbacterial vegetations or valvular thickening compared to those without APAs 3 . In a study of 93 patients with SLE, Nihoyannopoulos et al reported cardiac abnormalities in 54% of patients 8 . These comprised valvular lesions in 28%, pericardial effusion or thickening in 20% and regional or global left ventricular dysfunction in 5% of patients. Diffuse cardiomyopathy has also been reported 9 , but only in patients with SLE and secondary APS. Asymptomatic SLE patients have also been reported with left ventricular systolic dysfunction 10 .
Data concerning the relationship between APAs and myocardial infarction are conflicting. Some have found a high ACL to be an independent risk factor for myocardial infarction or cardiac death in a prospective cohort of healthy middle-aged men 11 . Zuckerman et al found ACL to be a marker for increased risk of subsequent myocardial infarction and thromboembolic events after acute MI in patients with PAPS 12 . Others were unable to show any link between ACL and recurrent events in those with documented ischaemic heart disease 13. Cardiac involvement in PAPS is extremely rare. Valvular abnormalities, pericardial effusion, coronary artery occlusion and intracardiac thrombi have been reported 14, 15 . Hasnie et al reported a single patient with isolated diastolic dysfunction in PAPS 16 .
Diffuse cardiomyopathy in patients with primary antiphospholipid antibody syndrome, let alone its first presentation with florid pulmonary oedema, has not been previously reported in the medical literature. The high troponin-I in our patient most likely signifies myocardial damage. It is possible that our patient suffered a myocardial infarction with angiographically normal coronary arteries; this can occur with arteriolar lesions. The prompt response to immunosuppressive therapy, the fact that her echocardiogram returned to normal and the absence of regional wall motion abnormalities, however, led us to believe that diffuse cardiomyopathy was the more likely cause in our patient.
An endomyocardial biopsy was considered but not performed. Fulminant myocarditis is a distinct clinical entity with a good long-term prognosis 17 and may have a viral 17 or an autoimmune basis 18 . The absence of other stigmata of viral infection, the negative serology for common viruses, the presence of other features of myocarditis as well as the response to steroids renders myocarditis less likely and autoimmune cardiomyopathy more likely in our patient. There are no controlled trials in this condition.
Our patient had high titres of IgG-ACL and anti-β2-glycoprotein I-IgG. This indicates exacerbation of her primary antiphospholipid antibody syndrome. The significance of elevated IgM-ACL is uncertain. The pathogenesis of thrombosis in APS is unclear and may include increased platelet activity, inhibition of prostacyclin release and inhibition of Protein C, Protein S and thrombomodulin system 19 . β2-glycoprotein I is an inhibitor of the intrinsic coagulation pathway 20 thus explaining why patients with APS have increased thrombotic disorders in vivo.
Patients with antiphospholipid antibodies are not uncommon and cardiomyopathy can result from primary antiphospholipid antibody syndrome. When such patients present with pulmonary oedema, even in the absence of previous cardiac disease, diffuse cardiomyopathy may be a possible diagnosis. Immunosuppressive therapy may be an effective adjunct to standard cardiopulmonary support in autoimmune cardiomyopathy. Such immunosuppression can restore normal cardiac function.
